Safety Concerns Doom Addex's Lead ADX10059 On Eve of Partnership
Elevated liver enzymes forced the Swiss biotech to halt a development of its lead compound in chronic indications, but the company insists a back-up shows promise.
Elevated liver enzymes forced the Swiss biotech to halt a development of its lead compound in chronic indications, but the company insists a back-up shows promise.